Abstract
Soursop consumption is beneficial to health, but there have been few clinical studies observing its benefit in human subjects. We investigated the effects of soursop supplementation on blood pressure (BP), serum uric acid (SUA), and kidney function. A total of 143 subjects were included in this randomized controlled trial. Subjects were selected from a prehypertension population dataset (n = 4190) in the “Mlati Study Database” in 2007 (using the Joint National Committee (JNC) 7 guideline). After 10 years, 143 samples showed essential prehypertension combined with high-normal SUA levels. Subjects were randomly allocated into two groups, i.e., the treatment and control group. For a 3-month period, the treatment group was given 2 × 100 g soursop fruit juice per day and the control group was not treated. Using the JNC 7 guideline, the treatment group showed a significantly lower mean systolic BP after being adjusted by three times of examinations (baseline, week 6 and 12) compared with the control group. Furthermore, the control group was more likely to have prehypertension, hypertension, and high-normal and high SUA levels after 6 weeks, as well as after 12 weeks, compared with the treatment group. An additional analysis using the 2017 ACC/AHA guideline for subjects with stage 1 hypertension showed results similar to that using the JNC 7 guideline. Moreover, it indicated that mean of both systolic and diastolic BP of the treatment group was significantly lower compared with the control group after 12 weeks of treatment. We conclude that soursop supplementation can lower BP and SUA levels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sutters M. Systemic hypertension. In: McPhee S, Papadakis MA, editors. Current medical diagnosis and treatment. New York: McGrawHill Lange; 2017. p. 439–71.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the JNC on prevention, detection and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc. 2003;289:2560–72.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary. A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:1269–324.
Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. N Eng J Med. 2006;354:1685–97.
Ishikawa Y, Ishikawa J, Ishikawa S, Kario K, Kajii E. Progression from prehypertension to hypertension and risk of cardiovascular disease. J Epidemiol. 2017;27:8–13.
Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.
Jonasson T, Ohlin AK, Gottsäter A, Hultberg B, Ohlin H. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease—a prospective randomized study of vitamin supplementation. Clin Chem Lab Med. 2005;43:628–34.
Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid levels as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–51.
Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potensial role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013;15:175–81.
Gavamukulya Y, Wamunyokoli F, El-Shemy HA. Annona muricata: is the natural therapy to most disease conditions including cancer growing in our backyard? A systematic review of its research history and future prospects. Asian Pac J Trop Med. 2017;10:835–48.
Coria-Tellez AV, Montalvo-Gonzalez E, Yahia EM, Obledo-Vazquez EN. Annona muricata: a comprehensive review on its traditional medicinal uses, phytochemicals, pharmacological activities, mechanisms of action and toxicity. Arab J Chem. 2016. https://doi.org/10.1016/j.arabjc.2016.01.004.
Moghadamtousi SZ, Fadaeinasab M, Nikzad S, Mohan G, Ali HM, Kadir HA. Annona muricata (Annonaceae): a review of its traditional uses, isolated acetogenins and biological activities. Int J Mol Sci. 2015;16:15625–28.
Adefegha SA, Oyeleye SI, Oboh G. Distribution of Phenolic Contents, Antidiabetic Potentials, Antihypertensive Properties, and Antioxidative Effects of Soursop (Annona muricata L.) Fruit Parts In Vitro. Biochem Res Int. 2015;2015:347673. https://doi.org/10.1155/2015/347673.
Ewadh MJ, Smaism MF, Jawad AM, Mkhlof S, Aljubouri OM, Ewadh MM. Using soursop extracts for natural gout treatment. Am J Biosci Bioeng. 2015;3:37–9.
Nwokocha CR, Owu DU, Gordon A, Thaxter K, McCalla G, Ozolua RI, et al. Possible mechanisms of action of the hypotensive effect of Annona muricata (soursop) in normotensive Sprague–Dawley rats. Pharm Biol. 2012;50:1436–41.
Adewole SO, Ojewole JAO. Protective effects of Annona Muricata Linn. (Annonaceae) leaf aqueous extract on serum lipid profiles and oxidative stress in hepatocytes of streptozotocin-treated diabetic rats. Afr J Tradit CAM. 2009;6:30–41.
Sja’bani M. Hypertension and renoprotective effects of high serum uric acid treatment. In: Annual Scientific Meeting of Indonesian Nephrology in Palembang. South Sumatra, Indonesia: Lembaga Penerbit Ilmu Penyakit Dalam, Bagian Ilmu Penyakit Dalam Fakultas Kedokteran UNSRI, Palembang, 2014.
Saleem U, Ejaz-ul-Haq M, Chudary Z, Ahmad B. Pharmacological screening of Annona muricata: a Review. Asian J Agric Biol. 2017;5:38–46.
Pinto AC, De Q, Cordeiro MCR, De Andrade SRM, Ferreira FR, Filgueiras HA, et al. Annona muricata. In: Williams JT, editor. Annona species, taxonomy and botany inter-national centre underutilised crops. Southampton, UK: University of Southampton. 2005. p. 3–16.
Chaparro SP, Tavera ML, Martínez JJ, Gil JH. Propiedades funcionales de la harina y de los aislados proteicos de la semilla de guanábana (Annona muricata). Rev UDCA Actual Divulgón Científica. 2014;17:151–9.
Sawant TP, Dongre RS. Bio-chemical compositional analysis of Annona muricata: a miracle fruit’s review. Int J Univ Pharm Bio Sci. 2014;3:82–104.
Djarot P, Badar M. Formulation and production of granule from Annona muricata fruit juice as antihypertensive instant drink. Int J Pharm Pharm Sci. 2017;9:18–22.
Li QL, Li BG, Zhang Y, Gao XP, Li CQ, Zhang GL. Three angiotensin-converting enzyme inhibitors from Rabdosia coetsa. Phytomedicine. 2008;15:386–8.
Ranilla LG, Kwon YI, Apostolidis E, Shetty K. Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and spices in latin America. Bioresour Technol. 2010;101:4676–89.
Oboh G, Ademiluyi AO, Akinyemi AJ, Henle T, Saliu JA, Schawarzenbolz U. Inhibitory effect of polyphenolrich extracts of jute leaf (Corchorus Olitorius) on key enzyme linked to type-2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting) in vitro. J Funct Foods. 2012;4:450-–8.
Ghayur MN, Gilani AH, Afridi MB, Houghton PJ. Cardiovascular effects of ginger aqueous extract and its phenolic constituents are mediated through multiple pathways. Vasc Pharm. 2005;43:234–41.
Wahyuni S, Putra-Manuaba IB, Rahayu-Artini NP, Wahyu-Dwijani S. Uric acid inhibition activity of annona muricata l leave extract in hyperuricemia-induced wistar rats. Adv Pure Appl Chem. 2012;2:86–90.
Moerfiah WardatunS, Rahma I. Effect of soursop juice (Annona muricata Linn) on decreasing of uric acid of Sprague–Dawley rats. J Tumbuh Obat Indones. 2012;5:63–72.
Lin KC, Lin HY, Chou P. The interaction between uric acid levels and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501–05.
Kong LD, Cai Y, Huang WW, Cheng CHK, Tan RX. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol. 2000;73:199–207.
Alta’ee AH, Ewadh MJ, Zaidan HK. Hormonal contents of two types of black seed (nigella sativa) oil: comparative study. Med J Babylon. 2006;3:17–22.
Acknowledgements
We would like to express our gratitude to the Mlati Study Group, who assisted with this research. We would also like to thank Prodia Laboratory for performing the laboratory examinations during this study.
Funding
This study was supported by the Mlati Study Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alatas, H., Sja’bani, M., Mustofa, M. et al. The effects of soursop supplementation on blood pressure, serum uric acid, and kidney function in a prehypertensive population in accordance with the 2017 ACC/AHA guideline. J Hum Hypertens 34, 223–232 (2020). https://doi.org/10.1038/s41371-019-0235-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-019-0235-6